Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment

Anti-Cancer Agents in Medicinal Chemistry, 8(4): 402-416.

Author(s): Elza T. Sakamoto-Hojo and Adayabalam S Balajee.

Affiliation: Center for Radiological Research,Department of Radiation Oncology, Columbia University Medical Center, VC-11, Room 239, 630 West, 168th Street, New York, NY 10032,USA.


Cancer is a disease of uncontrolled cellular proliferation. Chemotherapy and radiation therapy are the two main modalities for cancer treatment. However, some cancer types have been found to be refractory to these treatments. Additionally, certain chemicals that are used in clinical trials produce high cytotoxicity as a secondary effect. Hence, current research is focused on finding ways by which cancer cells can be specifically sensitized to apoptotic death with minimal or no secondary effects on normal healthy cells. Since the resistance of cancer cells to DNA damaging agents stems from the modulation of DNA repair pathways, pharmacological inhibition of these pathways has been emerging as an effective tool for cancer treatment. Inhibition of key proteins involved in the molecular cascade of DNA damage detection and repair such as poly (ADP) ribose polymerase I (PARP-1) and its interacting proteins [DNA dependent protein kinase (DNA-PK) and Cockayne syndrome group B (CSB)] has recently proven to be successful for the treatment of various types of cancer cells and tumor xenografts in vitro. This review summarizes some of the recent findings and the potential application of DNA repair inhibitors in cancer treatment.


Poly (ADP) ribose polymerase I, DNA-dependent protein kinase, Cockayne syndrome group B gene, nucleotide excision repair, base excision repair, DNA double strand breaks, DNA repair inhibitors and cancer treatment.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 4
First Page: 402
Last Page: 416
Page Count: 15
DOI: 10.2174/187152008784220302
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science